InvestorsHub Logo
Followers 85
Posts 6625
Boards Moderated 0
Alias Born 06/07/2016

Re: None

Saturday, 10/29/2022 8:42:30 AM

Saturday, October 29, 2022 8:42:30 AM

Post# of 731323
It will be interesting to hear the update from Timothy Cloughesy on the GBM AGILE trial during SNO:-

CTNI-38 - Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
Friday, November 18, 2022 7:30 PM – 9:30 PM ET Location: West/Central Hall

https://www.eventscribe.net/2022/SNO/searchGlobal.asp


GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Patrick Y. Wen, Ingo K. Mellinghoff, Meredith Becker Buxton, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, Gary B. Gordon, Mustafa Khasraw, Andrew B. Lassman, Michael Lim, James R. Perry, Kirk Tanner, Michael Weller, W. K. Alfred Alfred Yung, Timothy Francis Cloughesy, GBM AGILE Investigators

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS2074

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

https://clinicaltrials.gov/ct2/show/NCT03970447
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News